UNSPSC 51263006: Terazosin

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H25N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8L5014XET7, chemically known as 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine but generally known as terazosin, which bears US NIH Compound Identifier 5401. European Medicines Agency schedules Terazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10907MIG.

UNSPSC 51263006 Terazosin is a Commodity code that sits within a pharmaceutical taxonomy, but the recent state and local opportunities tagged under it bear little alignment with terazosin specifically — a selective alpha-1 adrenergic antagonist used to treat hypertension and benign prostatic hyperplasia. Instead, the solicitations reflect county and state health agencies procuring emergency medical supplies (naloxone and drug deactivation systems) and exploring direct-to-manufacturer pharmacy benefit models. State and local governments are using this code to tag health-related procurement across a wider pharmaceutical and medical-supply scope than the code's nominal name suggests. Issuing bodies include county health departments (Seminole County, Florida) and state health and human services agencies (Texas Health and Human Services Commission), indicating activity among both local county government and state-level health administration.

Geographically, the recent opportunities span Florida and Texas. The Seminole County IFB released on June 30, 2026 (due July 26, 2023 — note a date discrepancy in the source) solicits 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, requiring electronic bid submission through the county's e-Procurement Portal and compliance with E-Verify, drug-free workplace certification, and FEMA-related federal environmental regulations; the contract carries a two-year initial term with one-year renewal option. The Texas HHS Commission issued a Request for Information (RFI) on April 3, 2026 to explore vendor capacity for direct-to-manufacturer pharmacy contracting outside traditional pharmacy benefit manager arrangements, seeking information on direct contracting experience, negotiated net pricing models, and outcomes-based agreement capability to inform future formal solicitations. The code shows sparse recent activity in the state and local market, with no consistent pharmaceutical procurement pattern tied to terazosin itself.